The antiviral response to tenofovir disoproxil fumarate (TDF) is comparable in lamivudine (LAM)-naive and LAM-experienced subjects treated for chronic hepatitis B (CHB)

被引：3
|
作者：
Manns, M. [9 ]
Jeffers, L. [8 ]
Dalekos, G. [7 ]
Berg, T. [6 ]
Trepo, C. [5 ]
Roberts, S. [4 ]
Prieto, M. [3 ]
Rizzetto, M. [2 ]
Sorbel, J. [1 ]
Anderson, J. [1 ]
Mondou, E. [1 ]
Rousseau, F. [1 ]
机构：
[1] Gilead Sci Inc, Durham, NC USA
[2] Univ Turin, Dipartimento Gastroenterol, Turin, Italy
[3] Hosp La Fe, Serv Med Digestiva, E-46009 Valencia, Spain
[4] Alfred Hosp, Dept Gastroenterol, Melbourne, Vic, Australia
[5] Hop Hotel Dieu, Serv Hepatogastroenterol, F-69288 Lyon, France
[6] Charite Univ Med Berlin, Med Klin Schwerpunkt Hepatol & Gastroenterol, D-13353 Berlin, Germany
[7] Univ Thessaly, Sch Med, Larisa, Greece
[8] Univ Miami, Sch Med, Miami, FL USA
[9] Hannover Med Sch, D-30623 Hannover, Germany
来源：
JOURNAL OF HEPATOLOGY | 2008年 / 48卷
关键词：
D O I：
10.1016/S0168-8278(08)60076-8
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
74
引用
收藏
页码：S33 / S33
页数：1
相关论文
共 50 条
  • [1] The antiviral response to tenofovir disoproxil fumarate (TDF) is comparable in lamivudine (LAM)-naive and LAM-experienced subjects treated for chronic hepatitis B (CHB)
    Afdhal, Nezam
    Manus, Michael P.
    Jeffers, Lennox J.
    Nguyen, Tuan
    Berg, Thomas
    Dalekos, Georgios N.
    Trepo, Christian
    Roberts, Stuart K.
    Prieto, Martin
    Sorbel, Jeff
    Anderson, Jane
    Mondou, Elsa
    Rousseau, Franck
    GASTROENTEROLOGY, 2008, 134 (04) : A809 - A809
  • [2] Safety and efficacy in lamivudine (LAM) experienced chronic hepatitis B (CHB) patients treated for 2 years with tenofovir disoproxil fumarate (TDF)
    Roberts, S. K.
    Gane, E. J.
    Weilert, F.
    Sievert, W.
    George, J.
    Strasser, S. I.
    Kronborg, I.
    Heathcote, E. J.
    Marcellin, P.
    Sorbel, J.
    Rousseau, F.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2009, 24 : A299 - A299
  • [3] No Detectable Resistance to Tenofovir Disoproxil Fumarate (TDF) or TDF plus Emtricitabine (FTC/TDF) Combination Therapy Through 96 Weeks in Chronic Hepatitis B (CHB) Patients with Documented Resistance to Lamivudine (LAM)
    Corsa, Amoreena C.
    Liu, Yang
    Mitchell, Ben C.
    Flaherty, John F.
    Miller, Michael D.
    Kitrinos, Kathryn M.
    HEPATOLOGY, 2012, 56 : 382A - 383A
  • [4] COST-EFFECTIVENESS SIMULATION ANALYSIS OF TENOFOVIR DISOPROXIL FUMARATE (TDF), LAMIVUDINE (LAM), ADEFOVIR DIPIVOXIL (ADV) AND ENTECAVIR (ETV) IN HBEAG NEGATIVE (-) PATIENTS WITH CHRONIC HEPATITIS B (CHB) IN THE USA
    Deniz, H. B.
    Everhard, Francois
    HEPATOLOGY, 2008, 48 (04) : 744A - 744A
  • [5] Factors associated with regression of cirrhosis in patients with chronic hepatitis B (CHB) infection treated with tenofovir disoproxil fumarate (TDF)
    Gane, Ed
    Afdhal, Nezam
    Buti, Maria
    Elsome, Amanda M.
    Flaherty, John F.
    Martins, Eduardo
    Bekele, Neby
    Bornstein, Jeffrey D.
    Marcellin, Patrick
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2012, 27 : 164 - 164
  • [6] CHARACTERIZATION OF HBSAG KINETICS AND HBSAG SEROCONVERSION IN PATIENTS WITH CHRONIC HEPATITIS B (CHB) TREATED WITH TENOFOVIR DISOPROXIL FUMARATE (TDF)
    Marcellin, Patrick
    Heathcote, E. Jenny
    Buti, Maria
    Krastev, Zahary
    Jacobson, Ira M.
    de Man, Robert A.
    Dusheiko, Geoffrey M.
    Zeuzem, Stefan
    Barnes, Chris N.
    Lou, Lillian
    HEPATOLOGY, 2011, 54 : 1036A - 1036A
  • [7] HBSAG KINETICS IN PATIENTS WITH CHRONIC HEPATITIS B (CHB) TREATED WITH TENOFOVIR DISOPROXIL FUMARATE (TDF) FOR UP TO 4 YEARS
    Marcellin, P.
    Heathcote, E. J.
    Buti, M.
    Krastev, Z.
    Jacobson, I.
    de Man, R. A.
    Dusheiko, G.
    Zeuzem, S.
    Barnes, C.
    Ng, C.
    Lou, L.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S297 - S297
  • [8] No Detectable Resistance to Tenofovir Disoproxil Fumarate (TDF) when Given Alone or in Combination with Emtricitabine (FTC) in Chronic Hepatitis B (CHB) Patients with Documented Resistance to Lamivudine (LAM): Final 5 Year Results
    Berg, Thomas
    Gane, Edward J.
    Jablkowski, Maciej S.
    Urbanek, Petr
    Corsa, Amoreena C.
    Liu, Yang
    Kim, Kyungpil
    Flaherty, John F.
    Yurdaydin, Cihan
    Fung, Scott
    Kitrinos, Kathryn M.
    HEPATOLOGY, 2015, 62 : 1027A - 1027A
  • [9] Tenofovir disoproxil fumarate (TDF) is highly active for treatment of chronic hepatitis B in subjects with cirrhosis
    Wang, Chia
    Buti, Maria
    Hadziyannis, Stephanos J.
    Mathurin, Philipe
    Sherman, Morris
    Strasser, Simone I.
    Petersen, Joerg
    Tong, Myron J.
    Sorbel, Jeff
    Mondou, Elsa
    Anderson, Jane
    Rousseau, Franck
    GASTROENTEROLOGY, 2008, 134 (04) : A808 - A809
  • [10] Tenofovir disoproxil fumarate (TDF) is highly active for treatment of chronic hepatitis B in subjects with cirrhosis
    Butil, M.
    Hadziyannis, S.
    Mathurin, P.
    Urbanek, P.
    Sherman, M.
    Strasser, S.
    Wang, C.
    Petersen, J.
    Sorbel, J.
    Mondou, E.
    Anderson, J.
    Rousseau, F.
    JOURNAL OF HEPATOLOGY, 2008, 48 : S33 - S33
12345